Influence of polymers on the bioavailability of microencapsulated celecoxib

References

• Allemann E, Leroux J, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Advanced Drug Delivery Reviews 1998; 2–3: 171–189
   Google Scholar
• Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. European Journal of Pharmacology 2005; 2–3: 191–198
   Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England Journal of Medicine 2000; 343: 1520–1528, VIGOR Study Group.
   PubMed Web of Science ®Google Scholar
• De Jaeghere F, Allemann E, Cerny R, Galli B, Steulet AF, Muller I, Schutz H, Doelker E, Gurny R. pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs. AAPS PharmSciences 2001; 3: E8
   PubMedGoogle Scholar
• Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 2000; 16: 1659–1668
   Google Scholar
• Fitzgerald JF, Corrigan OI. Investigation of the mechanisms governing the release of levamisole from poly-lactide-co-glycolide delivery systems. Journal of Controlled Release 1996; 2: 125–132
   Google Scholar
• http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf, Food and Drug Agency. Decision memo on NSAID. Available online at:accessed 19 February 2007
   Google Scholar
• Garti N, Avrahami M, Aserin A. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. Journal of Colloid and Interface Science 2006; 299: 352–365
   PubMed Web of Science ®Google Scholar
• Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested control study. Lancet 2005; 365: 475–481
   PubMed Web of Science ®Google Scholar
• Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Molecular Pharmacology 2004; 1: 406–413
   PubMed Web of Science ®Google Scholar
• Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. Journal of Controlled Release 2006; 113: 38–42
   PubMed Web of Science ®Google Scholar
• Hombreiro-Perez M, Siepmann J, Zinutti C, Lamprecht A, Ubrich N, Hoffman M, Bodmeier R, Maincent P. Non-degradable microparticles containing a hydrophilic and-or a lipophilic drug preparation, characterization and drug release modeling. Journal of Controlled Release 2003; 88: 413–428
   PubMed Web of Science ®Google Scholar
• Hombreiro Perez M, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P. The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. Journal of Controlled Release 2000; 65: 429–438
   PubMed Web of Science ®Google Scholar
• Jeffery H, Davis SS, O'hagan DT. The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmaceutical Research 1993; 10: 362–368
   PubMed Web of Science ®Google Scholar
• Jeong JC, Lee J, Cho K. Effects of crystalline microstructure on drug release behavior of poly(epsilon-caprolactone) microspheres. Journal of Controlled Release 2003; 92: 249–258
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. Journal of Pharmaceutical Sciences 2002; 91: 760–768
   PubMed Web of Science ®Google Scholar
• Lee EJ, Lee SW, Choi HG, Kim CK. Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. International Journal of Pharmaceutics 2001; 218: 125–131
   PubMed Web of Science ®Google Scholar
• Luan X, Bodmeier R. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. Journal of Controlled Release 2006; 110: 266–272
   PubMed Web of Science ®Google Scholar
• Marounek M, Vovk SJ, Skrivanova V. Distribution of activity of hydrolytic enzymes in the digestive tract of rabbits. British Journal of Nutrition 1995; 73: 463–469
   PubMed Web of Science ®Google Scholar
• Mehta RC, Thanoo BC, Deluca PP. Peptide containing microspheres from low molecular mass and hydrophilic poly(D,L-lactide-co-glycolide). Journal of Controlled Release 1996; 41: 249–257
   Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. The Journal of the American Medical Association 2001; 286: 954–959
   PubMed Web of Science ®Google Scholar
• Nagarsenker MS, Joshi MS. Celecoxib—cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage. Drug Development and Industrial Pharmacy 2005; 31: 169–178
   PubMed Web of Science ®Google Scholar
• Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. The Journal of Pharmacology and Experimental Therapeutics 2001; 297: 638–645
   PubMed Web of Science ®Google Scholar
• Paulson SK, Zhang JY, Jessen SM, Lawal Y, Liu NW, Dudkowski CM, Wang YF, Chang M, Yang D, Findlay JW, et al. Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica 2000; 7: 731–744
   Google Scholar
• Sansdrap P, Moës AJ. Influence of manufacturing parameters on the size characteristics and the release profiles of nifedipine from poly(D,L-lactide-co-glycolide). International. Journal of Pharmaceutics 1993; 98: 157–164
   Web of Science ®Google Scholar
• Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003; 4: E33
   PubMedGoogle Scholar
• Sengel CT, Hascicek C, Gonul N. Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride. Journal of Microencapsulation 2006; 23: 135–152
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. The Journal of the American Medical Association 2000; 284: 1247–1255
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. The Journal of the American Medical Association 1999; 282: 1921–1928
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral boavailability of celecoxib. Biological and Pharmaceutical Bulletin 2004; 12: 1993–1999
   Google Scholar
• Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation. Journal of Drug Targeting 2004; 12: 549–557
   PubMed Web of Science ®Google Scholar
• Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech 2005; 6: E65–E73
   PubMed Web of Science ®Google Scholar
• Ubrich N, Schmidt C, Bodmeier R, Hoffman M, Maincent P. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. International Journal of Pharmaceutics 2005; 288: 169–175
   PubMed Web of Science ®Google Scholar
• Wang J, Wang BM, Schwendeman SP. Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. Journal of Controlled Release 2002; 82: 289–307
   PubMed Web of Science ®Google Scholar
• Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. International Journal of Pharmaceutics 2006; 317: 61–68
   PubMed Web of Science ®Google Scholar
• Zinutti C, Kedzierewicz F, Hoffman M, Maincent P. Preparation and characterization of ethylcellulose microspheres containing 5-fluorouracil. Journal of Microencapsulation 1994; 11: 555–563
   PubMed Web of Science ®Google Scholar